KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Accumulated Expenses: 2009-2025

Historic Accumulated Expenses for Jazz Pharmaceuticals (JAZZ) over the last 15 years, with Sep 2025 value amounting to $1.0 billion.

  • Jazz Pharmaceuticals' Accumulated Expenses rose 16.65% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 16.65%. This contributed to the annual value of $910.9 million for FY2024, which is 14.74% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Accumulated Expenses stood at $1.0 billion for Q3 2025, which was up 14.49% from $874.8 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Accumulated Expenses high stood at $1.1 billion for Q1 2025, and its period low was $374.0 million during Q1 2021.
  • In the last 3 years, Jazz Pharmaceuticals' Accumulated Expenses had a median value of $826.5 million in 2024 and averaged $851.1 million.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Accumulated Expenses surged by 110.21% in 2021 and then decreased by 1.16% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Accumulated Expenses (Quarterly) stood at $666.3 million in 2021, then grew by 20.55% to $803.3 million in 2022, then declined by 1.16% to $793.9 million in 2023, then rose by 14.74% to $910.9 million in 2024, then rose by 16.65% to $1.0 billion in 2025.
  • Its Accumulated Expenses was $1.0 billion in Q3 2025, compared to $874.8 million in Q2 2025 and $1.1 billion in Q1 2025.